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Abstract
Background: The annexins (ANXs) have diverse roles in tumor development and progression, however, their
clinical significance in cervical cancer has not been elucidated. The present study was to investigate the clinical
significance of annexin A2 (ANXA2) and annexin A4 (ANXA4) expression in cervical cancer.
Methods: ANXA2 and ANXA4 immunohistochemical staining were performed on a cervical cancer tissue
microarray consisting of 46 normal cervical epithelium samples and 336 cervical cancer cases and compared the
data with clinicopathological variables, including the survival of cervical cancer patients.
Results: ANXA2 expression was lower in cancer tissue (p = 0.002), whereas ANXA4 staining increased significantly in
cancer tissues (p < 0.001). ANXA2 expression was more prominent in squamous cell carcinoma (p < 0.001), whereas
ANXA4 was more highly expressed in adeno/adenosquamous carcinoma (p < 0.001). ANXA2 overexpression was
positively correlated with advanced cancer phenotypes, whereas ANXA4 expression was associated with resistance
to radiation with or without chemotherapy (p = 0.029). Notably, high ANXA2 and ANXA4 expression was
significantly associated with shorter disease-free survival (p = 0.004 and p = 0.033, respectively). Multivariate analysis
indicated that ANXA2+ (HR = 2.72, p = 0.003) and ANXA2+/ANXA4+ (HR = 2.69, p = 0.039) are independent
prognostic factors of disease-free survival in cervical cancer. Furthermore, a random survival forest model using
combined ANXA2, ANXA4, and clinical variables resulted in improved predictive power (mean C-index, 0.76)
compared to that of clinical-variable-only models (mean C-index, 0.70) (p = 0.006).
Conclusions: These findings indicate that detecting ANXA2 and ANXA4 expression may aid the evaluation of
cervical carcinoma prognosis.
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Background
Cervical cancer is the third most common type of cancer
in women worldwide and is the most prevalent female
malignancy in many developing countries [1, 2]. Although
vaccination and screening are excellent preventive
options, the prognosis remains poor once the cancer has
developed, particularly with bulky tumors or those with
the adenocarcinoma cell type [3–5]. Clinical factors, such
as stage, lymph node metastasis, and parametrial involve-
ment, may serve as prognostic markers, but they are
insufficient for accurately predicting survival. Thus, bio-
markers, including molecular markers, are needed, and
patient care would be improved considerably if tumor be-
havior could be prognosticated reliably at the time of ini-
tial diagnosis.
The annexins (ANXs) are a multigene family of calcium-
regulated phospholipid-binding proteins [6] that share the
ability to bind to negatively charged phospholipid
* Correspondence: ds123.bae@samsung.com; genejock@helix.nih.gov
†Equal contributors
2Department of Obstetrics and Gynecology, Samsung Medical Center,
Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu,
Seoul 135-710, Republic of Korea
1Experimental Pathology Laboratory, Laboratory of Pathology, Center for
Cancer Research, National Cancer Institute, National Institutes of Health, MSC
1500, Bethesda, MD 20892, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Choi et al. BMC Cancer  (2016) 16:448 
DOI 10.1186/s12885-016-2459-y
membranes in a calcium-dependent manner. This binding
is reversed by removing of calcium, and this reversible
membrane-binding ability is thought to be important for
vesicle aggregation and membrane organization [6, 7].
Twelve human ANX subfamilies (A1–A11 and A13) have
been described, and each ANX has different calcium sen-
sitivity and phospholipid specificity. In addition, the ANX
are distributed differentially [7] and have various functions
in cellular processes, such as calcium signaling, growth
regulation, cytoskeletal organization, cell division, and
apoptosis [6, 8]. Moreover, ANXs are involved in prolifera-
tion and invasion of tumor cells [9].
Up-regulation of annexin A2 (ANXA2) is associated
with progression and metastasis of high-grade glioma
[10] and hepatocellular [11], pancreatic [12], colorectal
[13], lung [14, 15], and breast cancers [16], whereas
down-regulation of ANXA2 occurs in patients with head
and neck squamous cell carcinoma [17, 18], esophageal
squamous cell carcinoma [19], and prostate cancer [20],
indicating that ANXA2 may be a useful marker for the
prognosis of these patients.
Annexin A4 (ANXA4), also called lipocortin IV and
endonexin I, is associated with progression, invasion, mi-
gration, and drug resistance of cancers [21–23]. Prior
studies have demonstrated that ANXA4 expression in-
creases in colorectal cancer [22, 24], invasive renal clear
cell carcinoma [25], and the clear cell carcinoma subtype
of ovarian cancer [26]. In contrast, Xin et al. reported
that ANXA4 expression decreases according to the pro-
gression of prostate cancer [27]. These data suggest that
changes in ANXA2 and ANXA4 expression are associ-
ated with a particular tumor type, indicating that ANXs
may be useful clinical biomarkers. However, knowledge
on the clinical and prognostic significance of ANXA2
and ANXA4 expression in patients with cervical cancer
is limited. In the present study, we investigated the prog-
nostic significance of ANXA2 and ANXA4 in cervical
cancers using immunohistochemistry and quantitative
image analyses. Furthermore, we evaluated a predictive
model of patient survival using combined ANX2 and
ANX4 expression, as well as clinical variables.
Methods
Patients and tumor samples
We retrieved 336 patients with cervical cancer who were
treated at the Department of Gynecologic Oncology,
Samsung Medical Center, Sungkyunkwan University
School of Medicine between 2002 and 2009. None of the
patients had undergone previous treatment including ra-
diation or chemotherapy. Patients with rare histology or
an advanced stage treated primarily with radiation were
excluded. As a control, 46 normal cervical epithelial
samples were obtained from patients treated for benign
uterine fibroids. The tissue specimens and medical
records were obtained with informed consent of all patients
and approval of the local research ethics committee (ap-
proval no. 2009-09-002-002 and 2015-07-122; Seoul, South
Korea). Additional paraffin blocks were provided by the
Korea Gynecologic Cancer Bank through Bio & Medical
Technology Development Program of the Ministry of
Education, Science and Technology, Korea (NRF-
2012M3A9B8021800). This study was additionally approved
by the Office of Human Subjects Research at the National
Institutes of Health.
All patients were treated primarily by radical hysterec-
tomy with or without pelvic/para-aortic lymph node dis-
section. Patients with risk factors, such as lymph node
metastasis, parametrial involvement, positive resection
margin, and stromal invasion of more than half of the
cervix, received adjuvant radiotherapy with or without
concurrent chemotherapy. Following treatment, the pa-
tients were followed up every 3 months for the first
2 years, every 6 months for the next 3 years, and every
year thereafter. Disease-free survival (DFS) was assessed
from the date of surgery to the date of recurrence or the
date of the last follow-up. Overall survival (OS) was de-
fined from the date of surgery to the time of death, or to
the date of last contact.
Western blotting
To detect the cellular localization of ANXA2 and
ANXA4, CaSki and HeLa cells were subjected to frac-
tionation, as described previously [28]. The cellular frac-
tions (10 μg) were separated by 4–12 % sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to a nitrocellulose membrane. After
blocking for 1 h with 5 % nonfat milk in TBST (50 mM
Tris, 150 mM NaCl, and 0.05 % Tween 20, pH 7.5), the
membrane was probed with the following primary anti-
bodies: anti-ANXA2 mouse monoclonal antibody (BD
Biosciences, Oxford, UK; clone # 5/ANXAII, 1:3000
dilution) and anti-ANXA4 rabbit polyclonal antibody
(Abcam, Cambridge, MA; cat. # ab33009, 1:1000 dilu-
tion). The membrane was incubated with the appropri-
ate secondary antibodies for 1 h at room temperature.
Immunoreactive bands were visualized using the Super-
Signal Chemiluminescence kit (Thermo Scientific,
Waltham, MA). Calnexin and lamin B1 were used as
cytoplasm and nuclear extract indicators, respectively, as
described previously [28].
Tissue microarray and immunohistochemistry
Tissue microarrays (TMAs) were constructed from tissue
blocks used for routine pathological evaluation. The ori-
ginal archived hematoxylin-eosin–stained slides were
reviewed by a pathologist. Areas in each case with the
most representative histology were selected, and a 0.6 mm
tissue core was taken from each donor block and extruded
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into the recipient array. At least three samples from separ-
ate tissue blocks were taken from donor tissue blocks to
fully represent each case. A section from each microarray
was stained with hematoxylin and eosin and examined by
light microscopy to check the adequacy of tissue
sampling.
ANX immunohistochemical staining was performed
using a standard streptavidin–peroxidase method, as de-
scribed previously [29]. In brief, serial 4-μm sections of
the TMA were deparaffinized in xylene and rehydrated
through a graded alcohol series. Heat-induced antigen re-
trieval was performed for 20 min in a pH 6.0 citrate anti-
gen retrieval buffer (Dako, Carpinteria, CA) or in a pH 9.0
buffer for ANXA4 and ANXA2, respectively. Endogenous
peroxidase activity was blocked with 3 % H2O2 for
10 min, and sections for ANXA4 were incubated with a
protein block (Dako) for another 10 min. The sections
were incubated with anti-ANXA2 mouse monoclonal
antibody at a 1:5000 dilution for 30 min and with anti-
ANXA4 rabbit polyclonal antibody at a 1:250 dilution for
2 h. The antigen-antibody reaction was detected with the
Dako EnVision +Dual Link System-HRP (Dako) and DAB
+ (3, 3′-diaminobenzidine; Dako). Tissue sections were
lightly counterstained with hematoxylin and examined by
light microscopy. Human renal tumors and human intes-
tinal villi were taken as positive ANXA2 and ANXA4 con-
trols, respectively. Negative controls were processed by
omitting the primary antibody.
Quantitative evaluation of immunostaining
Staining was quantitatively evaluated using computer-
assisted image analyzing software (Visiopharm, Hoersholm,
Denmark), as described previously [28]. In brief, slides were
scanned using a whole slide scanner (NanoZoomer 2.0,
Hamamatsu Photonics, Hamamatsu City, Japan) and
imported into Visiopharm software using the TMA work-
flow. Staining intensity was categorized as 0, 1+, 2+, and 3+
according to the distribution pattern across cores. A brown
staining intensity (0-negative, 1-weak, 2-moderate, and 3-
strong) was obtained using a predefined algorithm and op-
timized settings. The overall immunohistochemical score
(histoscore) was expressed as the percentage of positive
cells multiplied by their staining intensity (possible range,
0–300). Quantitative digital image analysis was possible in
all 366 cases with a wide range of histoscore. For the sur-
vival analysis, expression values were dichotomized (posi-
tive vs. negative) with the cut-off values showing the most
discriminative power (histoscore of 94 for ANXA2 and 51
for ANXA4) (Additional file 1: Figure S1).
In-silico analysis for GSE44001 and TCGA cervix
To examine the prognostic significance of the ANXA2
and ANXA4 mRNA expression, data from the Gene Ex-
pression Omnibus (GEO) and The Cancer Genome
Atlas (TCGA) were analyzed, as described previously
[29, 30]. A total of 300 patient samples were evaluable
for GSE44001 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc= GSE44001), and 265 of the samples were
also included in the immunohistochemical analysis of
this study. The pan-cancer normalized form of the cer-
vical cancer RNA‐seq data (version: 2015-02-24), which
were obtained using Illumina HiSeq (Illumina, San
Diego, CA, USA), were downloaded from TCGA Re-
search Network for the TCGA data analysis (http://can-
cergenome.nih.gov/). mRNA expression values were
dichotomized according to quartile values (lower than
25 percentile vs. higher than 75 percentile) for the sur-
vival analysis.
Statistical analysis
The statistical analysis was performed using R software
ver. 3.1.2. Student’s t-test or the Mann–Whitney U-test
was used to compare the continuous variables between
groups. Spearman’s rho coefficient analysis was used to
assess correlations between parameters. Survival distribu-
tions were estimated using the Kaplan–Meier method and
the relationships between survival and each parameter
were analyzed with the log-rank test. A Cox proportional
hazards model was created to identify independent predic-
tors of survival.
To assess the predictive power of integrating the mo-
lecular data (ANXA2 and ANXA4) with clinical vari-
ables, we modified the random survival forest (RSF)
method to include both clinical and molecular features
[31]. We used clinical features (International Federation
of Gynecology and Obstetrics (FIGO) stage, lymph node
metastasis, lymphovascular invasion, stromal depth of
invasion, parametrial involvement, and resection margin)
to build the clinical RSF model. We then combined the
molecular-level features with the clinical variables to
build a new RSF model. We randomly split the samples
into two groups for each set: 80 % as the training set
and 20 % as the test set. The RSF models were built
using the R package “Random Survival Forest” with the
default parameters. The models were applied to obtain
the test set for prediction, and the concordance index
(C-index) was calculated using the R package “surv-
comp”. The C-index is a nonparametric measure to
quantify the discriminatory power of a predictive model:
a C-index of 1 indicates perfect prediction accuracy and
a C-index of 0.5 is as good as a random guess [32]. The
above procedure was repeated 100 times to generate 100
C-index values for each set. To compare performance
between clinical variables only and the clinical variables
plus the ANXA2/ANXA4 data, we used the Wilcoxon
signed-rank test to calculate the p value. A p < 0.05 was
considered significant.
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Results
Clinicopathological patient characteristics
The clinicopathological characteristics of the 366 patients
are presented in Table 1. Mean age of the patients was 48.9
± 11.2 years. In total, 291 (86.6 %) patients were stage IIA
or less and 45 (13.4 %) were stage IB2 or IIB. Tumor sizes
ranged from 0.1 to 10.5 cm (mean, 3.21 cm). Postoperative
radiotherapy with or without concurrent chemotherapy
was administered to 160 patients (47.6 %). With a mean
follow-up time of 66 months (range, 1–143 months), forty-
six cases (13.7 %) developed recurrence and 20 patients
(6.0 %) died.
ANXA2 and ANXA4 expression
To examine the prognostic significance of ANXA2 and
ANXA4 mRNA expression, we analyzed the GEO and
Table 1 Correlation between annexin expression and the clinicopathological characteristics of patients with cervical cancer
Group No ANXA2 ANXA4
Mean histoscore [95 % CI] P value Mean histoscore (95 % CI) P value
Normal 46 133 [111–156] 0.002 34 [21–46] <0.001
Cancer 336 94 [88–101] 73 [65–81]
Age
<50 year 203 95 [87–103] 0.731 79 [68–89] 0.096
>50 year 133 93 [83–103] 65 [53–77]
FIGO Stage
≤ IIA 291 90 [83–97] 0.002 74 [66–83] 0.543
≥ IIB 45 121 [103–138] 67 [47–88]
Cell type
SCC 256 101 [93–108] <0.001 51 [44–58] <0.001
AD/ASC 80 73 [62–84] 145 [126–163]
Tumor size
≤4 cm 256 90 [82–97] 0.010 76 [66–85] 0.317
>4 cm 80 109 [96–121] 66 [49–83]
LVSI
Negative 202 88 [80–96] 0.019 83 [72–93] 0.005
Positive 133 104 [93–114] 60 [48–72]
Depth of invasion
<50 % 108 70 [60–80] <0.001 70 [55–84] 0.565
≥50 % 228 106 [98–113] 75 [65–85]
LN metastasis
Negative 256 88 [81–95] 0.002 76 [66–85] 0.250
Positive 80 113 [100–127] 65 [50–81]
PM involvement
Negative 305 92 [85–98] 0.031 74 [65–82] 0.662
Positive 31 118 [95–141] 68 [42–94]
Resection margin
Negative 323 94 [87–100] 0.420 75 [66–83] 0.032
Positive 13 111 [66–157] 43 [15–71]
Primary Treatment
OP only 171 82 [73–90] <0.001 78 [66–90] 0.354
OP + RT 70 110 [95–125] 71 [53–89]
OP + CCRT 90 107 [95–119] 68 [54–82]
Neoadjuvant 5 75 [45–105] 26 [8–59]
ANX annexin, FIGO International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, AD adenocarcinoma, ASC adenosquamous cell
carcinoma, LVSI lymphovascular space invasion, LN lymph node, PM parametrium, OP operation, RT radiotherapy, CCRT concurrent chemoradiation
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TCGA database. Patients with high ANXA4 mRNA ex-
pression showed significantly poorer OS (p = 0.027)
(Additional file 1: Figure S2).
Next, we performed Western blot using fractionated
CaSki and HeLa cell lysates to examine the specificity
anti-ANXA2 and anti-ANXA4 antibodies. ANXA4 was
predominantly detected in the cytosolic fraction,
whereas ANXA2 was detected in whole, cytosolic, and
nuclear lysates (Fig. 1). The purities of the cytosolic and
nuclear fractions were confirmed with calnexin and
lamin B1, respectively. In addition, we performed immu-
nohistochemistry in cervical cancer and normal tissues.
ANXA2 staining was detected only in the membranes of
normal cervical epithelium, whereas it was present in
both the membranes and cytoplasm in cancerous tissues.
ANXA4 staining was primarily observed in the cyto-
plasm. Representative examples of positive and negative
staining are shown in Fig. 2. A significant increase in
ANXA4 expression was detected in cancer tissues com-
pared with that in normal cervix (mean histoscores; 73
vs. 34, p < 0.001). In contrast, ANXA2 expression was
lower in cancer tissues than that in normal tissues (mean
histoscores; 94 vs. 133, p = 0.002). A positive correlation
was detected between mRNA and protein expression in
patients with both protein and mRNA expression data
from GSE44001 (Additional file 1: Figure S3).
ANXA2 and ANXA4 expression was associated with cell
type. ANXA2 was more highly expressed in squamous cell
carcinoma, whereas ANXA4 was expressed more promin-
ently in adeno-/adenosquamous carcinoma (p < 0.001 and
p < 0.001, respectively) (Table 1). The positive correlation
between mRNA and protein expression was more
prominent in squamous cell carcinoma for ANXA2 and in
adenocarcinoma for ANXA4 (Additional file 1: Figure S3),
suggesting that these ANXs potentially have different roles
according to cervical cancer cell type.
ANXA2 expression was associated with a more aggres-
sive cancer phenotype (Table 1). High ANXA2 expression
was positively correlated with higher stage, large-sized tu-
mors, lymphovascular space invasion, stromal invasion
depth, lymph node metastasis, and parametrial involve-
ment (p = 0.002, p = 0.01, p = 0.019, p < 0.001, p = 0.002,
and p = 0.031, respectively). In contrast, ANXA4 expres-
sion was not associated with an aggressive phenotype, al-
though it was more highly expressed in cancer tissue
compared with normal tissue. To examine the association
between ANX protein expression and chemo and/or
radiotherapy resistance, we grouped patients receiving
radiotherapy and/or chemotherapy into “resistant”
(recurred within 3 years) or “sensitive” (no recurrence
within 3 years) groups. As shown in Fig. 3, ANXA4 ex-
pression was significantly correlated with resistance to
chemotherapy and/or radiation (p = 0.029).
Prognostic significance of ANXA2 and ANXA4
The estimated five-year DFS and OS rates for the whole
group were 87 % (95 % confidence interval [CI] 83–91)
and 96 % (95 % CI, 93–98), respectively. ANXA2 and
ANXA4 expression was significantly associated with poor
DFS (p = 0.004 and p = 0.033, respectively) and OS (p =
0.245 and p = 0.032, respectively) (Fig. 4). The 5-year DFS
rates were 80 and 81 % in patients with positive ANXA2
and ANXA4 expression, respectively, compared with 92
and 91 % in patients with negative expression. Similarly,
5-year OS rates were 94 and 94 % in patients with positive
ANXA2 and ANXA4 expression respectively, compared
with 97 and 97 % for patients with negative expressions.
The combination of markers showed even greater dis-
criminatory power and identified subgroups with 5-year
DFS rates of 71 % vs. 95 % and 5-year OS rates of 91 % vs.
98 % using the ANXA2 and ANXA4 combination. The
Cox proportional hazards model showed that expression
of ANXA2 and combined ANXA2/ANXA4 expression
remained an independent prognostic factor for DFS (haz-
ard ratio [HR] = 2.72, 95 % CI, 1.41–5.27, p = 0.003; HR =
2.69, 95 % CI, 1.05–6.90, p = 0.039, respectively) (Table 2,
Additional file 2: Table S1).
Assessment of the prognostic value of ANXA2 and ANXA4
To examine whether molecular data and ANXA2 and
ANXA4 protein expression provided additional prognostic
power when used with the clinical variables, we compared
the predictive models using only the clinical variables and
the combined clinical/molecular variables. The combined
clinical/molecular-variable model predicting death re-









Fig. 1 Subcellular localization of annexin A2 (ANXA2) and annexin A4
(ANXA4) in cervical cancer cell lines. Whole (W), cytosolic (C), and
nuclear (N) fractions from CaSki and HeLa cells were analyzed by
Western blot. Calnexin and lamin B1 were used as an index for the
cytosolic and nuclear fractions, respectively
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0.76; range, 0.73–0.79) compared to the clinical-variable-
only model (mean C-index, 0.70; range, 0.68–0.73) (p =
0.006) (Fig. 5). For models predicting recurrence, the com-
bined clinical and ANXA2/ANXA4 model showed similar
predictive power (mean C-index, 0.76, 95 % CI, 0.75–0.78)
to clinical-variable-only model (mean C-index, 0.75, 95 %
CI, 0.73–0.77).
Discussion
ANXA2 exists as a monomer or heterotetramer com-
posed of two ANXA2 molecules and partner molecules
and has four forms, including secrete, membrane-bound,
cytoplasmic, and nuclear forms [33]. In the present
study, levels of ANXA2 expression decreased in cervical
cancer tissues compared to those in normal tissues;
however, differences in subcellular localization were de-
tected (Fig. 2). ANXA2 was detected very strongly near
the cytosolic membrane in normal cervical epithelial
specimens, whereas it was detected in both membranes
and the cytoplasm in cervical cancer tissues. This finding
suggests that ANXA2 may not just play a role as a Ca2+
binding protein on the membrane surface, but also as a
component of dynamic trafficking pathways, such as
exocytosis and endocytosis [6]. Enhanced trafficking
pathways are an emerging feature of cancers during ini-
tiation and progression [34]. Concomitantly, the increase
of ANXA2 expression was associated with a more ag-
gressive phenotype among cervical cancer tissues exam-
ined in this study (Table 1). Nuclear ANXA2 was
detected by Western blot in cervical cancer cell lines
(Fig. 1). In general, ANXA2 expression in the nucleus is
considered a cell-cycle-dependent phenomenon [33].
We also found that ANXA2 and ANXA4 were differen-















Fig. 2 Representative immunohistochemical images of annexin A2 (ANXA2) and annexin A4 (ANXA4) in cervical cancer tissue. ANXA2 expression
was strongly detected in the membranes of normal tissues (a), whereas ANXA4 staining was weakly observed in the cytoplasm of normal tissues
(e). Negative staining demonstrated a lack of ANXA2 (b) and ANXA4 (f) expression. ANXA2 staining was mainly observed in the membranes of
squamous cell carcinoma (c) and adenocarcinoma (d) cervical cancer tissues. ANXA4 staining was restricted to the cytoplasm of squamous cell
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P = 0.029 
a b
Fig. 3 Association between chemoradiation response and annexin A2 (ANXA2) and annexin A4 (ANXA4) expression. ANXA4 expression was
significantly correlated with resistance to chemoradiation (p = 0.029) (b), whereas ANXA2 expression was not (a)
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each ANX potentially has a different role in squamous
cell carcinoma or adenocarcinoma in patients with cer-
vical cancer. Furthermore, we demonstrated that high
ANXA2 and ANXA4 expression predicted poor survival
in patients with cervical cancer, which was supported by
the improved predictive power of a model using com-
bined clinical-ANXA2/ANXA4-variables. These results
suggest that ANXA2 and ANXA4 protein analyses can
be a prerequisite in diagnoses of cervical cancers and
may guide the patient therapy.
Few reports are available on ANX expression in cer-
vical cancer or its correlation with prognosis. Jin et al.
evaluated the significance of ANXA2 protein expression






















Fig. 4 Kaplan-Meier plot for disease-free survival (DFS) and overall survival (OS) categorized based on annexin A2 (ANXA2) and annexin A4 (ANXA4)
protein expression. High ANXA2 expression was associated with short DFS (p = 0.004) (a) but not with short OS (p = 0.245) (d). High ANXA4 expression
was associated with short DFS (p = 0.033) (b) and OS (p = 0.032) (e). The association between high ANXA2/ANXA4 expression with DFS (c) and OS (f)
was significantly different from that of low ANXA2/ANXA4 expression (p < 0.001 and p = 0.017, respectively). P-values were obtained from log-rank tests
Table 2 Univariate and multivariate analyses of the association between prognostic variables and disease-free survival in patients
with cervical cancer
Risk factor Univariate Multivariate
Hazard ratio [95 % CI] P value Hazard ratio [95 % CI] P value
FIGO stage (> IIB) 2.44 [1.24–4.82] 0.010 1.38 [0.67–2.84] 0.381
Cell type (AD) 2.88 [1.62–5.14] <0.001 4.58 [2.48–8.45] <0.001
LN metastasis 4.13 [2.31–7.38] <0.001 3.82 [2.03–7.18] <0.001
Tumor size (>4 cm) 1.7 [0.92–3.15] 0.092 1 [0.51–1.95] 0.994
PM involvement 2.24 [1.05–4.81] 0.038 1.23 [0.55–2.76] 0.62
ANXA2+ 2.33 [1.28–4.25] 0.006 2.72 [1.41–5.27] 0.003
ANXA4+ 1.89 [1.04–3.41] 0.036 1.28 [0.64–2.56] 0.479
ANXA2+/ANXA4+ 4.21 [1.75–10.09] 0.001 2.69 [1.05–6.90] 0.039
CI confidential interval, ANX annexin, FIGO International Federation of Gynecology and Obstetrics, AD adenocarcinoma, LN lymph node, PM parametrial
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patients with cervical cancer [35]. ANXA2 protein ex-
pression correlates with tumor response to chemother-
apy, and ANXA2 expression in stromal cells was an
independent prognostic factor for DFS. No report has
evaluated ANXA4 expression and prognosis of cervical
cancer.
ANXA2 expression was associated with an aggressive
phenotype, such as higher stage, large-sized tumors,
lymphovascular invasion, invasion depth, lymph node
metastasis, and parametrial involvement in the present
study. ANXA2 promotes cell invasion in malignancies of
the breast, brain, liver, and pancreas [10–12, 36, 37] and
enhances cell motility and cell adhesion of prostate and
hepatocellular carcinoma cells [38, 39]. One of the
mechanisms enhancing cancer metastasis is the inter-
action between ANXA2 and its binding proteins, which
play an important role in the tumor microenvironment
[40]. ANXA2 binds with plasminogen and tissue plas-
minogen activator on the cell surface, leading to the
conversion of plasminogen to plasmin, which plays a key
role activating metalloproteinases and degrading the
extracellular matrix components essential for metastatic
progression. In addition, after binding to collagen I, ca-
thepsin B and tenascin-C, ANXA2 assists in maintaining
plasticity and rearrangement of the actin cytoskeleton
which is important in metastasis [41, 42]. In support of
these findings, ANXA2 siRNA or neutralizing antibodies
significantly inhibit motility and invasion of ovarian cancer
cells in vitro and in vivo [40].
Persistent infection of human papillomavirus (HPV) is
highly associated with cancers arising in squamous epi-
thelium, and approximately 90 % of cervical cancer cases
are associated with HPV as a causative agent [43]. HPV
must gain entry into host basal cells of the epithelium to
deliver its double-stranded DNA to the nucleus and the
HPV capsid proteins play a vital role in these steps [44].
However, the mechanisms of entry and the specific re-
ceptors directly involved in the internalization of onco-
genic HPVs remains unclear. Dziduszko and Ozbun have
shown that HPV16 particles interact with ANXA2 in as-
sociation with S100A10 as a heterotetramer at the cell
surface in a Ca2+-dependent and likely a heparin-
sulfonated proteoglycan-dependent manner [45]. They
confirmed the role of ANXA2 in HPV16 infection by
showing that (i) early HPV16 binding results in extracel-
lular translocation of ANXA2, (ii) ANXA2 cointernalizes
and mediates intracellular trafficking of HPV16 and (iii)
anti-A2 and anti-S100A10 antibodies block HPV16 in-
fection at different stages of HPV16 infection. Notably,
Woodham et al. have reported that small molecular in-
hibitors of the ANXA2 heterotetramer prevent HPV16
pseudovirions infection in HeLa cells [46]. These data
indicate that ANXA2 may play a critical role in tumori-
genesis, which could potentially be applied as a thera-
peutic target of cervical cancer.
The role of individual ANXs has been reported in various
cancer types in previous studies. Mussunoor and Murray
overviewed the role of each ANX on a variety of cellular
functions including cell proliferation, apoptosis, angiogen-
esis, invasion and differentiation [9]. Except ANXA9 and
ANXA13, changes in the expression of individual ANXs
were observed in a diversity of cancers, including gastric
carcinoma, colorectal cancer, pancreatic cancer, breast







































Fig. 5 Comparison of survival predictive power of the clinical variables and the combined clinical and molecular data. We used the clinical
variables (FIGO stage, lymph node metastasis, lymphovascular invasion, stromal depth of invasion, parametrial involvement, and resection margin)
for the analysis. During 100 random splits, 80 % of all samples were used to train the model and the remaining 20 % were used as the test set for
the C-index calculations. The white box highlights the model built from the clinical variables, and the grey-colored box highlights the models integrating the
ANXA2 and ANXA4 data and clinical variables. The combined clinical and ANXA2/ANXA4 model predicting recurrence showed similar predictive power with
the clinical variable model (a). However, the combined clinical/molecular-variable model showed better performance than that based only on clinical variables
in the model predicting death (Mann-Whitney U-test, p= 0.006) (b). The dashed lines mark the C-index equivalent to a random guess (C-index = 0.5)
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melanoma, but not in cervical cancer [9]. In order to as-
sume the influence of HPV on ANX expression in cervical
cancer, we analyzed the TCGA pan-cancer data. The level
of ANXA2 mRNA expression is relatively high in the cer-
vical and head/neck cancers which are largely correlated
with HPV infection, whereas ANXA4 mRNA expression
showed intermediate level in the both cancers (Additional
file 1: Figure S4).
The association between ANXA2 and ANXA4 expres-
sion and specific HPV type infection could not be
assessed in the present study due to the lack of clinical
information about the specific HPV type infection in pa-
tients. Therefore, we analyzed the TCGA database in
order to assess the relationship between ANXA2 and
ANXA4 mRNA expression and specific HPV type infec-
tion. The HPV type information is only available from
22 patients with cervical cancer. ANXA2 and ANXA4
mRNA expression showed no difference among the
HPV types (Additional file 1: Figure S5). Studies evaluat-
ing the relation between a different type of HPV and
ANX function will give further insight about the role of
ANXs in cervical carcinogenesis.
The poor survival in patients who expressed ANXA2
and ANXA4 seen in this study may have been due to the
correlation with aggressive phenotype, particularly in
those who expressed ANXA2. However, another import-
ant possibility is an association with radio/chemo resist-
ance. ANXA4 expression was significantly associated with
chemo/radio resistance in this study. Although the func-
tions of ANXA4 are not completely known, many studies
have identified the involvement of ANX in membrane per-
meability [47], exocytosis [48, 49], and regulation of ion
channels [50]. These functions may explain the involve-
ment of ANXA4 in modulating drug resistance through
efflux of intracellular chemotherapy drugs in cancer cells.
In addition to increased efflux, modulation of the tran-
scriptional activity of nuclear factor kappa-light-chain-en-
hancer of activated B cells (NF-kB) has been suggested as
a mechanism of chemoresistance. A previous study identi-
fied an association between ANXA4 and NF-kB transcrip-
tional activity. Jeon et al. [51] showed that ANXA4
suppresses NF-kB transcriptional activity, which is signifi-
cantly upregulated immediately after etoposide treatment.
ANXA4 translocate to the nucleus together with p50 and
imparts greater resistance to apoptosis stimulation by
etoposide. They concluded that ANXA4 differentially
modulates the NF-kB signaling pathway, depending on
the interaction with p50 and intracellular Ca2+ levels. We
also shown previously that overexpression and nuclear
localization of ANXA4 are related to chemoresistance and
poor survival in patients with serous papillary ovarian car-
cinomas [52]. In contrast to ANXA4, the association be-
tween ANXA2 and chemoresistance has not been well
studied and remains unclear.
Conclusions
In conclusion, our results show that ANXA2 and
ANXA4 protein expression, alone or in combination, are
independently poor prognostic factors of survival in pa-
tients with cervical cancer. This information can be
helpful in the management of patients with cervical
cancer. Patients who express high levels of ANXA2 and
ANXA4 should be considered for closer follow-up or in-
tensified adjuvant treatment.
Additional files
Additional file 1: Figure S1. Histoscore distribution of annexin A2
(ANXA2) and annexin A4 (ANXA4) expression using a quantitative image
analysis. Dashed vertical lines indicate the chosen cut-off values (ANXA2
= 94 and ANXA4 = 51). Figure S2. Kaplan-Meier survival curves according
to annexin A2 (ANXA2) and annexin A4 (ANXA4) mRNA expression. Data
were retrieved from the GEO (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE44001) and TCGA (RNA-seq databases (version: 2015-02-24).
The mRNA expression values were dichotomized according to quartile
values (lower than 25 percentile vs. higher than 75 percentile). Figure S3.
Correlations between annexin A2 (ANXA2) and annexin A4 (ANXA4)
mRNA and protein expression. Positive correlations were noted in both
ANXA2 (Spearman’s rho= 0.273, p< 0.001) and ANXA4 (Spearman’s rho= 0.293,
p< 0.001). A subgroup analysis showed a positive correlation between ANXA2
expression and squamous cell carcinoma (Spearman’s rho= 0.255, p< 0.001)
and ANXA4 expression and adenocarcinoma (Spearman’s rho= 0.389, p= 0.002).
Figure S4. ANXA2 and ANXA4mRNA expression according to cancer types. (Data
from cBioPortal Cancer Genomics: www.cbioportal.org). Figure S5. ANXA2 and
ANXA4mRNA expression according to HPV type infected. Data was retrieved
from TCGA (RNA-seq database version 2015-02-24). (PPTX 1250 kb)
Additional file 2: Table S1. Univariate and multivariate analyses of the
association between prognostic variables and overall survival in patients
with cervical cancer. (DOCX 15 kb)
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